Peter Speck

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1958268/publications.pdf Version: 2024-02-01



DETED SDECK

#	Article	IF	CITATIONS
1	Marine mollusc extracts—Potential source of SARSâ€CoVâ€2 antivirals. Reviews in Medical Virology, 2022, 32, e2310.	8.3	2
2	Thirty-Day Unplanned Readmissions Following Hospitalisation for Atrial Fibrillation in Australia and New Zealand. Heart Lung and Circulation, 2022, 31, 944-953.	0.4	2
3	Efficacy of the PlasmaShield®, a Non-Thermal, Plasma-Based Air Purification Device, in Removing Airborne Microorganisms. Electrochem, 2022, 3, 276-284.	3.3	1
4	Potential for bacteriophage therapy for <i>Staphylococcus aureus</i> pneumonia with influenza A coinfection. Future Microbiology, 2021, 16, 175-184.	2.0	4
5	The Promise of viral phage therapy in hernia mesh infection, is this the biological â€~silver bullet' of the future?. ANZ Journal of Surgery, 2020, 90, 2161-2164.	0.7	1
6	Efficacy of phage cocktail AB-SA01 therapy in diabetic mouse wound infections caused by multidrug-resistant Staphylococcus aureus. BMC Microbiology, 2020, 20, 204.	3.3	41
7	The microbial abundance dynamics of the paediatric oral cavity before and after sleep. Journal of Oral Microbiology, 2020, 12, 1741254.	2.7	10
8	Economic evaluations considering costs and outcomes of diabetic foot ulcer infections: A systematic review. PLoS ONE, 2020, 15, e0232395.	2.5	22
9	Efficacy of Lytic Phage Cocktails on Staphylococcus aureus and Pseudomonas aeruginosa in Mixed-Species Planktonic Cultures and Biofilms. Viruses, 2020, 12, 559.	3.3	23
10	Mini-review: efficacy of lytic bacteriophages on multispecies biofilms. Biofouling, 2019, 35, 472-481.	2.2	30
11	A systematic review protocol for examining 30-day readmission costs for atrial fibrillation patients. BMJ Open, 2019, 9, e032101.	1.9	0
12	Patients' and caregivers' needs, experiences, preferences and research priorities in spiritual care: A focus group study across nine countries. Palliative Medicine, 2018, 32, 216-230.	3.1	155
13	Faecal microbiota transplantation donor stools need screening for poliovirus. Gut, 2018, 67, 1559-1560.	12.1	1
14	ls phage therapy suitable for treating chronic sinusitisStaphylococcus aureusinfection?. Future Microbiology, 2018, 13, 605-608.	2.0	4
15	Antiviral Defense and Innate Immune Memory in the Oyster. Viruses, 2018, 10, 133.	3.3	48
16	Palliative care service in Cyprus, a population-based needs assessment based on routine mortality data. Progress in Palliative Care, 2017, 25, 215-223.	1.2	1
17	Long-Term Safety of Topical Bacteriophage Application to the Frontal Sinus Region. Frontiers in Cellular and Infection Microbiology, 2017, 7, 49.	3.9	44
18	Culture and spirituality: essential components of palliative care. Postgraduate Medical Journal, 2016, 92, 341-345.	1.8	19

Peter Speck

#	Article	IF	CITATIONS
19	Primed for success: Oyster parents treated with poly(I:C) produce offspring with enhanced protection against Ostreid herpesvirus type I infection. Molecular Immunology, 2016, 78, 113-120.	2.2	55
20	Safety and efficacy of phage therapy via the intravenous route. FEMS Microbiology Letters, 2016, 363, fnv242.	1.8	119
21	Marine Snails and Slugs: a Great Place To Look for Antiviral Drugs. Journal of Virology, 2015, 89, 8114-8118.	3.4	40
22	Antiviral immunity in marine molluscs. Journal of General Virology, 2015, 96, 2471-2482.	2.9	62
23	Oyster viperin retains direct antiviral activity and its transcription occurs via a signalling pathway involving a heat-stable haemolymph protein. Journal of General Virology, 2015, 96, 3587-3597.	2.9	26
24	Evidence that the major hemolymph protein of the Pacific oyster, Crassostrea gigas, has antiviral activity against herpesviruses. Antiviral Research, 2014, 110, 168-174.	4.1	26
25	Anti-viral gene induction is absent upon secondary challenge with double-stranded RNA in the Pacific oyster, Crassostrea gigas. Fish and Shellfish Immunology, 2014, 39, 492-497.	3.6	32
26	Ontogeny and water temperature influences the antiviral response of the Pacific oyster, Crassostrea gigas. Fish and Shellfish Immunology, 2014, 36, 151-157.	3.6	74
27	Safety and efficacy of topical bacteriophage and ethylenediaminetetraacetic acid treatment of <i>Staphylococcus aureus</i> infection in a sheep model of sinusitis. International Forum of Allergy and Rhinology, 2014, 4, 176-186.	2.8	50
28	Bacteriophage Reduces Biofilm of Staphylococcus Aureus Ex Vivo Isolates from Chronic Rhinosinusitis Patients. American Journal of Rhinology and Allergy, 2014, 28, 3-11.	2.0	55
29	Holistic models for end of life care: Establishing the place of culture. Progress in Palliative Care, 2014, 22, 80-87.	1.2	12
30	Immunological changes in response to herpesvirus infection in abalone Haliotis laevigata and Haliotis rubra hybrids. Fish and Shellfish Immunology, 2013, 34, 688-691.	3.6	15
31	Antibiotics: Avert an impending crisis. Nature, 2013, 496, 169-169.	27.8	12
32	Influence of elevated temperatures on the immune response of abalone, Haliotis rubra. Fish and Shellfish Immunology, 2012, 32, 732-740.	3.6	79
33	In vitro antiviral activity against herpes simplex virus in the abalone Haliotis laevigata. Journal of General Virology, 2011, 92, 627-637.	2.9	35
34	Variation in the antiviral and antibacterial activity of abalone Haliotis laevigata, H. rubra and their hybrid in South Australia. Aquaculture, 2011, 315, 242-249.	3.5	39
35	Effects of micro and macroalgal diet supplementations on growth and immunity of greenlip abalone, Haliotis laevigata. Aquaculture, 2011, 320, 91-98.	3.5	64
36	Signal Transduction through the B Cell Antigen Receptor Is Normal in Ataxia-Telangiectasia B Lymphocytes. Journal of Biological Chemistry, 2002, 277, 4123-4127.	3.4	3

PETER SPECK

#	Article	IF	CITATIONS
37	Epstein–Barr Virus Entry into Cells. Virology, 2000, 277, 1-5.	2.4	58
38	Epstein-Barr Virus Entry Utilizing HLA-DP or HLA-DQ as a Coreceptor. Journal of Virology, 2000, 74, 2451-2454.	3.4	105
39	Infection of Breast Epithelial Cells With Epstein-Barr Virus Via Cell-to-Cell Contact. Journal of the National Cancer Institute, 2000, 92, 1849-1851.	6.3	42
40	Epstein–Barr virus lacking latent membrane protein 2 immortalizes B cells with efficiency indistinguishable from that of wild-type virus. Journal of General Virology, 1999, 80, 2193-2203.	2.9	51